Becker's Healthcare May 24, 2024
Mariah Taylor

FDA advisers have recommended the approval of Guardant Health’s blood test to detect colon or rectal cancers — but it also raised some concerns, NBC News reported May 23.

The panel voted 7-2 in favor of approving Gaurdant’s test, Shield. If the FDA does approve it, it will be the second blood-based test for colon cancer, competing with Epigenomics’ Epi proColon, which was approved in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: FDA, Govt Agencies, Medical Devices, Patient / Consumer, Provider
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article